MedTrace Logo

Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial

NCT00502463 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2024-02-07

No results posted yet for this study

Summary

The purpose of the trial is to determine the feasibility of an induction chemotherapy with radio-immunotherapy in patients with head and neck cancer stage III/IV

Conditions

Interventions

DRUG

Docetaxel

75mg/m² day 1

DRUG

Cisplatin

75mg/m² day 1

DRUG

5-FU

750mg/m²/day day 1-5

RADIATION

Radiotherapy

standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks

DRUG

Cetuximab

250mg/m²/week after an initial loading dose of 400mg/m²

Sponsors & Collaborators

  • Change of sponsor 2008: new sponsor AGMT

    collaborator UNKNOWN

  • Austrian South Oncology Group

    lead NETWORK

Principal Investigators

  • Felix Keil, MD · LKH Leoben, Dept. for Hemato-Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-03
Primary Completion
2010-01-19
Completion
2014-01-19

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502463 on ClinicalTrials.gov